{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:28:44Z","timestamp":1790072924525,"version":"4.0.1"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,8,2]]},"DOI":"10.18632\/oncotarget.10448","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T01:13:39Z","timestamp":1467854019000},"page":"49786-49799","source":"Crossref","is-referenced-by-count":12,"title":["FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia"],"prefix":"10.18632","volume":"7","author":[{"given":"Albert","family":"Catal\u00e0","sequence":"first","affiliation":[{"name":"Pediatric Hematology and Oncology Department, Hospital Sant Joan de D\u00e9u, University of Barcelona, Esplugues de Llobregat, Barcelona, Spain"},{"name":"National Biomedical Research Institute on Rare Diseases (CIBER ER), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Institut de Recerca Pedi\u00e0trica Hospital Sant Joan de D\u00e9u (IRP-HSJD), Esplugues de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00e7al","family":"Pastor-Anglada","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Barcelona, Institute of Biomedicine (IBUB), Barcelona, Spain"},{"name":"Oncology Program, National Biomedical Research Institute of Liver and Gastrointestinal Diseases (CIBER EHD), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Institut de Recerca Pedi\u00e0trica Hospital Sant Joan de D\u00e9u (IRP-HSJD), Esplugues de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liska","family":"Caviedes-C\u00e1rdenas","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Barcelona, Institute of Biomedicine (IBUB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Malatesta","sequence":"additional","affiliation":[{"name":"Hematology Laboratory, Hospital Sant Joan de D\u00e9u, University of Barcelona, Esplugues de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Rives","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology Department, Hospital Sant Joan de D\u00e9u, University of Barcelona, Esplugues de Llobregat, Barcelona, Spain"},{"name":"National Biomedical Research Institute on Rare Diseases (CIBER ER), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Institut de Recerca Pedi\u00e0trica Hospital Sant Joan de D\u00e9u (IRP-HSJD), Esplugues de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Vega-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Hematology Laboratory, Hospital Sant Joan de D\u00e9u, University of Barcelona, Esplugues de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Cam\u00f3s","sequence":"additional","affiliation":[{"name":"National Biomedical Research Institute on Rare Diseases (CIBER ER), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Hematology Laboratory, Hospital Sant Joan de D\u00e9u, University of Barcelona, Esplugues de Llobregat, Barcelona, Spain"},{"name":"Institut de Recerca Pedi\u00e0trica Hospital Sant Joan de D\u00e9u (IRP-HSJD), Esplugues de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Fern\u00e1ndez-Calotti","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Barcelona, Institute of Biomedicine (IBUB), Barcelona, Spain"},{"name":"Oncology Program, National Biomedical Research Institute of Liver and Gastrointestinal Diseases (CIBER EHD), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Institut de Recerca Pedi\u00e0trica Hospital Sant Joan de D\u00e9u (IRP-HSJD), Esplugues de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,7,6]]},"reference":[{"key":"1","first-page":"121344","article-title":"Relation between age, immunophenotype anddrug resistance in 395 children with acute lymphoblastic leukemia\u2014implications for treatment of infants","author":"Veerman","year":"1998","journal-title":"Leukemia"},{"key":"2","first-page":"16623","article-title":"A critical review of which children with acute myeloid leukaemia need stem cell procedures","author":"Hasle","year":"2014","journal-title":"Br J Haematol"},{"key":"3","first-page":"921565","article-title":"D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia","author":"Pieters","year":"2007","journal-title":"Haematologica"},{"key":"4","first-page":"2774","article-title":"Blood. Blood","author":"Pieters","year":"2007","journal-title":"United States"},{"key":"5","first-page":"1191872","article-title":"Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study","author":"Pieters","year":"2012","journal-title":"Blood"},{"key":"6","first-page":"1133","article-title":"Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling","author":"Wilkins","year":"2002","journal-title":"Cancer Cell"},{"key":"7","first-page":"1185905","article-title":"Nordic Society of Pediatric Hematology and Oncology (NOPHO). Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia","author":"Hasle","year":"2011","journal-title":"Blood"},{"key":"8","first-page":"1031901","article-title":"Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia","author":"Shinagawa","year":"2004","journal-title":"Blood"},{"key":"9","first-page":"1062484","article-title":"Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia","author":"Pieters","year":"2005","journal-title":"Blood"},{"key":"10","first-page":"4764","article-title":"FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns","author":"Fioretos","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"11","first-page":"3173","article-title":"Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification","author":"Korsmeyer","year":"2003","journal-title":"Cancer Cell"},{"key":"12","first-page":"105812","article-title":"FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression","author":"Small","year":"2005","journal-title":"Blood"},{"key":"13","first-page":"1212734","article-title":"Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mielobl\u00e1sticas. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy","author":"Mart\u00ed","year":"2013","journal-title":"Blood"},{"key":"14","first-page":"613","article-title":"Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets","author":"P\u00e9rez-Torras","year":"2015","journal-title":"Front Pharmacol"},{"key":"15","first-page":"79380","article-title":"Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells","author":"Capizzi","year":"1987","journal-title":"J Clin Invest"},{"key":"16","first-page":"11809","article-title":"Drug transporter pharmacogenetics in nucleoside-based therapies","author":"Pastor-Anglada","year":"2010","journal-title":"Pharmacogenomics"},{"key":"17","first-page":"1011270","article-title":"Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia","author":"Pieters","year":"2003","journal-title":"Blood"},{"key":"18","first-page":"16877","article-title":"RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia","author":"Viswabandya","year":"2015","journal-title":"Pharmacogenomics"},{"key":"19","first-page":"931388","article-title":"The human equilibrative nucleoside transporter 1 mediatescytarabine sensitivity in childhood acute myeloid leukaemia","author":"Kaspers","year":"2005","journal-title":"Br J Cancer"},{"key":"20","first-page":"3901001","article-title":"FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression","author":"Miyachi","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"21","first-page":"1083654","article-title":"Clinical implications of FLT3 mutations in pediatric AML","author":"Radich","year":"2006","journal-title":"Blood"},{"key":"22","first-page":"32219","article-title":"High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial","author":"Sborgia","year":"2014","journal-title":"J Clin Oncol"},{"key":"23","first-page":"26460","article-title":"Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia","author":"Tzortzatou-Stathopoulou","year":"2009","journal-title":"Med Oncol"},{"key":"24","first-page":"30735","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","author":"Rocha","year":"2012","journal-title":"J Clin Oncol"},{"key":"25","first-page":"3041","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","author":"Korsmeyer","year":"2002","journal-title":"Nat Genet"},{"key":"26","first-page":"370240","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","author":"Silverman","year":"2007","journal-title":"Lancet"},{"key":"27","first-page":"1033544","article-title":"FLT3 mutations in childhood acute lymphoblastic leukemia","author":"Korsmeyer","year":"2004","journal-title":"Blood"},{"key":"28","first-page":"70238","article-title":"Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer","author":"Pastor-Anglada","year":"2006","journal-title":"Oncology"},{"key":"29","first-page":"301324","article-title":"Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies","author":"Pastor-Anglada","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"30","first-page":"12253","article-title":"Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine","author":"Dumontet","year":"2003","journal-title":"Br J Haematol"},{"key":"31","first-page":"31405","article-title":"Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia","author":"Uchiyama","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"32","first-page":"25707","article-title":"Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches","author":"Rutella","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"33","first-page":"13786","article-title":"Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG","author":"Russell","year":"1999","journal-title":"Leukemia"},{"key":"34","first-page":"32411","article-title":"FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children","author":"Oakhill","year":"1999","journal-title":"Med Pediatr Oncol"},{"key":"35","first-page":"59417","article-title":"Clofarabine in pediatric acute leukemia: current findings and issues","author":"Arceci","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"36","first-page":"27517","article-title":"Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience","author":"Cetin","year":"2010","journal-title":"Pediatr Hematol Oncol"},{"key":"37","first-page":"993885","article-title":"A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cellsand","author":"Small","year":"2002","journal-title":"Blood"},{"key":"38","first-page":"8703","article-title":"FLT3 as a therapeutic target in childhood acute leukemia","author":"Armstrong","year":"2007","journal-title":"Curr Drug Targets"},{"key":"39","first-page":"1937","article-title":"Targeting FLT3 to treat leukemia","author":"Levis","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"40","first-page":"97683","article-title":"FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance","author":"Levis","year":"2013","journal-title":"Int J Hematol"},{"key":"41","first-page":"10554","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","author":"Clark","year":"2005","journal-title":"Blood"},{"key":"42","first-page":"1033669","article-title":"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia","author":"Small","year":"2004","journal-title":"Blood"},{"key":"43","first-page":"1041145","article-title":"studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects","author":"Small","year":"2004","journal-title":"Blood"},{"key":"44","first-page":"201368","article-title":"Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner","author":"Small","year":"2006","journal-title":"Leukemia"},{"key":"45","first-page":"151979","article-title":"Macrophages require different nucleoside transport systems for proliferation and activation","author":"Felipe","year":"2001","journal-title":"FASEB J"},{"key":"46","first-page":"296575","article-title":"Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs","author":"Pastor-Anglada","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"47","first-page":"994326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","author":"Illmer","year":"2002","journal-title":"Blood"},{"key":"48","first-page":"1002393","article-title":"Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors","author":"Linch","year":"2002","journal-title":"Blood"},{"key":"49","first-page":"28513589","article-title":"All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism","author":"Pastor-Anglada","year":"2010","journal-title":"J Biol Chem"},{"key":"50","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12885-015-1249-2","article-title":"Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors","volume":"15","author":"Mazo","year":"2015","journal-title":"BMC Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T10:29:44Z","timestamp":1589279384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,6]]},"references-count":50,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2016,8,2]]}},"alternative-id":["10448","27391351"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10448","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,6]]}}}